PD-L1, which is expressed on tumours and antigen-presenting cells, binds to PD-1 on the surface of tumour-infiltrating lymphocytes, thereby exerting an inhibitory effect on lymphocyte function and enabling immune evasion by the tumour 51, 80. Here, PDCD1 is linked to neoplasm.